At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET
Werewolf Therapeutics presented Phase 1/1b data for WTX-124 (IL-2 prodrug) and Phase 1b/2 data for WTX-330 (IL-12 prodrug) at SITC 2026, showing safety and durable antitumor activity in advanced solid tumors. The company aligned with the FDA on a recommended Phase 2 dose of 18 mg IV Q2W for WTX-124. The data support further development in multiple tumor types, but the company remains early-stage with a $49M market cap and no approved products.
- Phase 1/1b trial of WTX-124 reported data from 155 patients; 3 objective responses in monotherapy dose escalation including a durable CR in CSCC.
- Phase 1b/2 trial of WTX-330 reported data from 24 patients; one confirmed PR in gallbladder cancer.
- FDA aligned on WTX-124 RP2D of 18 mg IV Q2W for monotherapy and combination with pembrolizumab.
- Both molecules were administered safely in the outpatient setting with no vascular leak syndrome.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access